Symbols / SLDB Stock $6.53 -0.61% Solid Biosciences Inc.

Healthcare • Biotechnology • United States • NMS
SLDB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Alexander G. Cumbo
Exch · Country NMS · United States
Market Cap 642.88M
Enterprise Value 286.80M
Income -191.78M
Sales —
FCF (ttm) -110.97M
Book/sh 3.80
Cash/sh 3.87
Employees 121
Insider 10d —
IPO Jan 26, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.34
PEG —
P/S —
P/B 1.72
P/C —
EV/EBITDA -1.47
EV/Sales —
Quick Ratio 12.57
Current Ratio 13.10
Debt/Eq 5.52
LT Debt/Eq —
EPS (ttm) -1.92
EPS next Y -1.96
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-12
Earnings (prior) 2026-03-19
ROA -32.03%
ROE -57.37%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 98.45M
Shs Float 53.74M
Insider Own 0.74%
Instit Own 101.67%
Short Float 11.22%
Short Ratio 8.12
Short Interest 9.60M
52W High 8.87
vs 52W High -26.35%
52W Low 3.79
vs 52W Low 72.30%
Beta 2.43
Impl. Vol. 48.71%
Rel Volume 0.35
Avg Volume 1.16M
Volume 405.75K
Target (mean) $17.38
Tgt Median $16.00
Tgt Low $11.00
Tgt High $26.00
# Analysts 13
Recom Strong_buy
Prev Close $6.57
Price $6.53
Change -0.61%
About

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.38
Mean price target
2. Current target
$6.49
Latest analyst target
3. DCF / Fair value
$-20.29
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.49
Low
$11.00
High
$26.00
Mean
$17.38

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-03 main HC Wainwright & Co. Buy → Buy $25
2026-05-18 reit Wedbush Outperform → Outperform $16
2026-05-13 main Wedbush Outperform → Outperform $16
2026-05-13 main Piper Sandler Overweight → Overweight $18
2026-03-25 main JP Morgan Overweight → Overweight $12
2026-03-23 reit HC Wainwright & Co. Buy → Buy $20
2026-03-20 init Guggenheim — → Buy $26
2026-03-20 main Chardan Capital Buy → Buy $15
2026-03-20 reit Needham Buy → Buy $19
2026-03-12 main Wedbush Outperform → Outperform $17
2026-03-12 main Chardan Capital Buy → Buy $15
2026-03-11 reit Wedbush Outperform → Outperform $14
2026-02-09 reit Needham Buy → Buy $16
2026-01-14 reit Needham Buy → Buy $16
2025-12-04 init Needham — → Buy $16
2025-11-05 main Citigroup Buy → Buy $14
2025-11-05 main JP Morgan Overweight → Overweight $11
2025-11-04 main Barclays Overweight → Overweight $9
2025-11-04 main Chardan Capital Buy → Buy $15
2025-08-14 main Chardan Capital Buy → Buy $15
News
RSS: Latest SLDB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-02 SMITH IAN F Director — 3,441 — —
2026-02-18 HOWTON DAVID TYRONNE Chief Operating Officer — 7,469 $5.82 $43,494
2026-02-18 CUMBO ALEXANDER Chief Executive Officer — 16,644 $5.82 $96,923
2026-02-18 GANOT ILAN Director — 2,658 $5.82 $15,478
2026-02-18 TAN KEVIN Chief Financial Officer — 5,404 $5.82 $31,469
2026-02-18 HANRAHAN JESSIE Officer — 4,134 $5.82 $24,074
2026-02-18 HERZICH PAUL Chief Technology Officer — 3,616 $5.82 $21,057
2026-02-18 BROOKS GABRIEL M.D. Officer — 89,466 $5.92 $529,639
2026-02-13 HOWTON DAVID TYRONNE Chief Operating Officer — 14,687 — —
2026-02-13 CUMBO ALEXANDER Chief Executive Officer — 30,031 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
8.09
Operating Revenue
0.00
0.00
0.00
-100.00%
8.09
Operating Expense
179.21
+38.14%
129.73
+24.36%
104.31
-2.84%
107.37
Research And Development
140.32
+45.52%
96.43
+25.95%
76.56
-2.37%
78.42
Selling General And Administration
38.88
+16.77%
33.30
+19.98%
27.75
-4.13%
28.95
General And Administrative Expense
38.88
+16.77%
33.30
+19.98%
27.75
-4.13%
28.95
Other Gand A
38.88
+16.77%
33.30
+19.98%
27.75
-4.13%
28.95
Total Expenses
179.21
+38.14%
129.73
+24.36%
104.31
-2.84%
107.37
Operating Income
-179.21
-38.14%
-129.73
-24.36%
-104.31
-5.08%
-99.27
Total Operating Income As Reported
-179.21
-38.14%
-129.73
-24.44%
-104.25
+2.07%
-106.45
EBITDA
-177.57
-45.67%
-121.90
-31.09%
-92.99
+4.00%
-96.87
Normalized EBITDA
-171.52
-46.41%
-117.15
-25.89%
-93.06
+13.78%
-107.92
Reconciled Depreciation
1.64
-33.36%
2.46
-4.88%
2.58
+7.18%
2.41
EBIT
-179.21
-44.11%
-124.36
-30.11%
-95.58
+3.73%
-99.27
Total Unusual Items
-6.05
-27.37%
-4.75
-7639.68%
0.06
-99.43%
11.06
Total Unusual Items Excluding Goodwill
-6.05
-27.37%
-4.75
-7639.68%
0.06
-99.43%
11.06
Special Income Charges
—
0.00
-100.00%
0.06
-99.43%
11.06
Restructuring And Mergern Acquisition
—
0.00
+100.00%
-0.06
+99.43%
-11.06
Net Income
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Pretax Income
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Net Non Operating Interest Income Expense
10.11
+10.71%
9.13
+27.82%
7.14
+173.01%
2.62
Interest Expense Non Operating
—
0.34
-22.73%
0.44
—
Net Interest Income
10.11
+10.71%
9.13
+27.82%
7.14
+173.01%
2.62
Interest Expense
—
0.34
-22.73%
0.44
—
Interest Income Non Operating
10.11
+6.74%
9.47
+24.89%
7.58
+189.83%
2.62
Interest Income
10.11
+6.74%
9.47
+24.89%
7.58
+189.83%
2.62
Other Income Expense
-5.23
-27.53%
-4.10
-453.89%
1.16
-89.15%
10.68
Other Non Operating Income Expenses
0.82
+26.38%
0.65
-40.46%
1.09
+387.40%
-0.38
Gain On Sale Of Security
-6.05
-27.37%
-4.75
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Net Income From Continuing Operation Net Minority Interest
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Net Income From Continuing And Discontinued Operation
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Net Income Continuous Operations
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Normalized Income
-168.28
-40.29%
-119.95
-24.84%
-96.08
+0.99%
-97.04
Net Income Common Stockholders
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Diluted EPS
-1.99
+34.97%
-3.06
+36.65%
-4.83
+52.18%
-10.10
Basic EPS
-1.99
+34.97%
-3.06
+36.65%
-4.83
+52.18%
-10.10
Basic Average Shares
87.50
+114.38%
40.82
+105.27%
19.88
+133.60%
8.51
Diluted Average Shares
87.50
+114.38%
40.82
+105.27%
19.88
+133.60%
8.51
Diluted NI Availto Com Stockholders
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Total Other Finance Cost
—
—
—
-2.62
Line Item Trend 2023-12-31
Total Assets
164.94
Current Assets
129.73
Cash Cash Equivalents And Short Term Investments
123.64
Cash And Cash Equivalents
74.02
Other Short Term Investments
49.62
Receivables
—
Accounts Receivable
—
Prepaid Assets
3.98
Restricted Cash
—
Other Current Assets
2.11
Total Non Current Assets
35.20
Net PPE
33.16
Gross PPE
45.90
Accumulated Depreciation
-12.73
Properties
0.00
Machinery Furniture Equipment
2.33
Construction In Progress
0.41
Other Properties
42.68
Leases
0.48
Other Non Current Assets
2.04
Total Liabilities Net Minority Interest
38.46
Current Liabilities
14.52
Payables And Accrued Expenses
6.25
Payables
2.03
Accounts Payable
2.03
Current Accrued Expenses
4.21
Pensionand Other Post Retirement Benefit Plans Current
5.95
Current Debt And Capital Lease Obligation
2.32
Current Capital Lease Obligation
2.32
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
0.02
Total Non Current Liabilities Net Minority Interest
23.94
Long Term Debt And Capital Lease Obligation
23.94
Long Term Capital Lease Obligation
23.94
Other Non Current Liabilities
—
Stockholders Equity
126.48
Common Stock Equity
126.48
Capital Stock
0.02
Common Stock
0.02
Preferred Stock
0.00
Share Issued
20.39
Ordinary Shares Number
20.39
Treasury Shares Number
0.00
Additional Paid In Capital
785.20
Retained Earnings
-658.75
Gains Losses Not Affecting Retained Earnings
0.01
Other Equity Adjustments
0.01
Total Equity Gross Minority Interest
126.48
Total Capitalization
126.48
Working Capital
115.22
Invested Capital
126.48
Total Debt
26.27
Capital Lease Obligations
26.27
Net Tangible Assets
126.48
Tangible Book Value
126.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-156.29
-56.27%
-100.01
-6.19%
-94.18
+3.88%
-97.98
Cash Flow From Continuing Operating Activities
-156.29
-56.27%
-100.01
-6.19%
-94.18
+3.88%
-97.98
Net Income From Continuing Operations
-174.32
-39.80%
-124.70
-29.87%
-96.02
-11.67%
-85.98
Depreciation Amortization Depletion
1.64
-33.36%
2.46
-4.88%
2.58
+7.18%
2.41
Depreciation
1.64
-33.36%
2.46
-4.88%
2.58
+7.18%
2.41
Depreciation And Amortization
1.64
-33.36%
2.46
-4.88%
2.58
+7.18%
2.41
Other Non Cash Items
2.13
-72.32%
7.70
+165.16%
2.90
+115.72%
-18.48
Stock Based Compensation
16.91
+60.79%
10.52
+37.95%
7.62
+1.17%
7.54
Operating Gains Losses
6.05
+27.37%
4.75
+1170.05%
0.37
—
Gain Loss On Investment Securities
6.05
+27.37%
4.75
—
—
Gain Loss On Sale Of PPE
—
—
0.37
0.00
Change In Working Capital
-6.82
-339.37%
2.85
+132.14%
-8.87
-140.39%
-3.69
Change In Receivables
—
—
0.00
-100.00%
0.11
Changes In Account Receivables
—
—
0.00
-100.00%
0.11
Change In Prepaid Assets
-7.99
-226.91%
-2.44
-508.86%
0.60
-83.82%
3.69
Change In Payables And Accrued Expense
2.96
-57.58%
6.97
+190.17%
-7.73
-1419.28%
0.59
Change In Accrued Expense
4.05
-15.02%
4.77
+168.41%
-6.97
-219.46%
5.83
Change In Payable
-1.09
-149.57%
2.21
+388.61%
-0.76
+85.44%
-5.25
Change In Account Payable
-1.09
-149.57%
2.21
+388.61%
-0.76
+85.44%
-5.25
Change In Other Working Capital
—
—
—
-8.08
Change In Other Current Liabilities
-1.79
-6.56%
-1.68
+3.40%
-1.74
—
Investing Cash Flow
-58.45
-263.38%
-16.09
-266.02%
9.69
-83.62%
59.16
Cash Flow From Continuing Investing Activities
-58.45
-263.38%
-16.09
-266.02%
9.69
-83.62%
59.16
Net PPE Purchase And Sale
-1.07
-64.56%
-0.65
+57.16%
-1.51
+37.27%
-2.42
Purchase Of PPE
-1.15
-76.30%
-0.65
+56.83%
-1.51
+49.75%
-3.02
Sale Of PPE
0.09
+1600.00%
0.01
0.00
-100.00%
0.60
Capital Expenditure
-1.15
-76.30%
-0.65
+56.83%
-1.51
+49.75%
-3.02
Net Investment Purchase And Sale
-57.39
-271.74%
-15.44
-237.78%
11.20
-62.71%
30.05
Purchase Of Investment
-235.89
-15.44%
-204.34
-74.01%
-117.43
+35.75%
-182.76
Sale Of Investment
178.50
-5.51%
188.90
+46.85%
128.63
-39.56%
212.81
Net Business Purchase And Sale
—
—
0.00
-100.00%
31.52
Financing Cash Flow
194.45
+58.81%
122.44
+3821.75%
3.12
-95.83%
74.83
Cash Flow From Continuing Financing Activities
194.45
+58.81%
122.44
+3821.75%
3.12
-95.83%
74.83
Net Issuance Payments Of Debt
-0.72
-52.85%
-0.47
0.00
-100.00%
2.08
Issuance Of Debt
—
—
0.00
-100.00%
2.14
Repayment Of Debt
-0.72
-52.85%
-0.47
0.00
+100.00%
-0.07
Long Term Debt Issuance
—
—
0.00
-100.00%
2.14
Long Term Debt Payments
-0.72
-52.85%
-0.47
0.00
+100.00%
-0.07
Net Long Term Debt Issuance
-0.72
-52.85%
-0.47
0.00
-100.00%
2.08
Net Common Stock Issuance
194.74
+59.47%
122.12
+4006.12%
2.97
-95.90%
72.55
Common Stock Payments
-1.68
+67.11%
-5.11
0.00
—
Repurchase Of Capital Stock
-1.68
+67.11%
-5.11
0.00
—
Proceeds From Stock Option Exercised
0.43
-45.72%
0.79
+436.49%
0.15
-27.09%
0.20
Changes In Cash
-20.30
-420.19%
6.34
+107.79%
-81.37
-325.96%
36.01
Beginning Cash Position
82.19
+8.36%
75.85
-51.76%
157.22
+29.71%
121.21
End Cash Position
61.89
-24.70%
82.19
+8.36%
75.85
-51.76%
157.22
Free Cash Flow
-157.44
-56.40%
-100.67
-5.19%
-95.69
+5.24%
-100.99
Amortization Of Securities
-1.87
+47.83%
-3.59
-49.17%
-2.41
-1133.48%
0.23
Common Stock Issuance
196.42
+54.38%
127.23
+4177.98%
2.97
-95.90%
72.55
Issuance Of Capital Stock
196.42
+54.38%
127.23
+4177.98%
2.97
-95.90%
72.55
Sale Of Business
—
—
0.00
-100.00%
31.52
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category